知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

478 条记录 (耗时 0.058 秒)

    Dioxomolybdenum (VI) complex compounds as catalysts for polyurethane compositions
    7.
    发明授权
    Dioxomolybdenum (VI) complex compounds as catalysts for polyurethane compositions 有权
    二恶唑（VI）配合物作为聚氨酯组合物的催化剂

    公开(公告)号：US09422390B2

    公开(公告)日：2016-08-23

    申请号：US14358925

    申请日：2012-12-12

    申请人： SIKA TECHNOLOGY AG

    发明人： Urs Burckhardt ,  Rita Cannas

    IPC分类号： C08G18/08 ,  C08L75/00 ,  C08G18/00 ,  C07C49/92 ,  C08G18/22 ,  C07F11/00 ,  C08G18/48 ,  C09D175/08 ,  C09J175/08 ,  C08G18/76

    CPC分类号： C08G18/222 ,  C07C235/80 ,  C07D295/108 ,  C07F11/005 ,  C08G18/12 ,  C08G18/4812 ,  C08G18/4866 ,  C08G18/7671 ,  C08G2190/00 ,  C08K5/56 ,  C09D175/08 ,  C09J175/08 ,  C08G18/307

    摘要： The invention relates to dioxomolybdenum (VI) complex compounds of the formula MoO2(L)x(Y)2-x, where the ligand L has the formula (I). Such complex compounds are suitable in particular as catalysts for one- and two-component polyurethane compositions. The invention also relates to two-component polyurethane compositions including at least one polyisocyanate as the first component, at least one polyol as the second component, and at least one such dioxomolybdenum (VI) complex compound as the catalyst. The invention further relates to one-component polyurethane compositions comprising at least one polyurethane prepolymer with isocyanate groups, which are made from at least one polyisocyanate with at least one polyol, and comprising such a dioxomolybdenum (VI) complex compound as the catalyst. The invention additionally relates to different uses of said polyurethane compositions.

    摘要翻译： 本发明涉及式MoO2（L）x（Y）2-x的二氧钼（VI）络合物，其中配体L具有式（I）。 这种络合物特别适用于单组分和双组分聚氨酯组合物的催化剂。 本发明还涉及包含作为第一组分的至少一种多异氰酸酯，作为第二组分的至少一种多元醇和至少一种作为催化剂的这种二氧六钼（VI）络合物化合物的双组分聚氨酯组合物。 本发明还涉及包含至少一种具有异氰酸酯基团的聚氨酯预聚物的单组分聚氨酯组合物，其由至少一种多异氰酸酯与至少一种多元醇制成，并且包含这种作为催化剂的二氧钼（VI）配位化合物。 本发明还涉及所述聚氨酯组合物的不同用途。

    Therapeutic Agent for Type 2 Diabetes
    8.
    发明申请
    Therapeutic Agent for Type 2 Diabetes 审中-公开
    2型糖尿病治疗剂

    公开(公告)号：US20160060235A1

    公开(公告)日：2016-03-03

    申请号：US14780052

    申请日：2014-03-28

    申请人： NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY ,  KUMAMOTO HEALTH SCIENCE UNIVERSITY

    发明人： Kazuhito Tomizawa ,  Fanyan Wei ,  Kengo Inoue ,  Tadashi Okawara

    IPC分类号： C07D295/108 ,  C07D211/58

    CPC分类号： C07D295/108 ,  A61K31/192 ,  A61K31/197 ,  A61K31/4545 ,  A61K31/495 ,  A61K31/496 ,  A61K45/06 ,  C07D211/58 ,  C07D215/48 ,  C07D295/15 ,  C07D295/185 ,  C07D333/20 ,  Y02A50/473 ,  A61K2300/00

    摘要： An object of the present invention is to provide a novel therapeutic agent for a patient with type 2 diabetes, a cause of which is the abnormal synthesis of insulin attributed to the abnormal modification of tRNALys (UUU) in pancreatic β cells having Cdkal1 gene mutation. The present inventors have used (1) a screening system using E. coli in which correct translation into luciferase requires frameshift resulting from mistranslation during protein translation, (2) a screening system using the pancreatic islet of Langerhans isolated from a pancreatic β cell-specific Cdkal1-deficient mouse, and (3) a screening system using a pancreatic β cell-specific Cdkal1-deficient mouse, and found that a compound represented by any of the following formulas (I) to (III) can serve as a therapeutic agent for a patient with type 2 diabetes with Cdkal1 gene mutation resulting in the reduced ability to secrete insulin.

    摘要翻译： 本发明的目的是提供一种用于2型糖尿病患者的新型治疗剂，其原因是由于胰腺中tRNALys（UUU）的异常修饰引起的胰岛异常合成; 细胞具有Cdkal1基因突变。 本发明人已经使用（1）使用大肠杆菌的筛选系统，其中正确翻译成荧光素酶需要在蛋白质翻译过程中由于错译造成的移码，（2）使用从胰腺分离的朗格汉斯胰岛的筛选系统; 细胞特异性Cdkal1缺陷小鼠，和（3）使用胰腺的筛选系统; 细胞特异性Cdkal1缺陷小鼠，发现由下式（I）至（III）中任一项表示的化合物可用作具有Cdkal1基因突变的2型糖尿病患者的治疗剂，导致其降低的能力 分泌胰岛素